Non-Sterile Powder Free Blue Nitrile Examination Gloves Tested for Use with Chemotherapy Drugs

Q: Who is the manufacturer of Non-Sterile Powder Free Blue Nitrile Examination Gloves Tested for Use with Chemotherapy Drugs?

Maxter Glove Manufacturing Sdn Bhd filed the 510(k) submission for Non-Sterile Powder Free Blue Nitrile Examination Gloves Tested for Use with Chemotherapy Drugs (K172864).

Q: What is the FDA product code for Non-Sterile Powder Free Blue Nitrile Examination Gloves Tested for Use with Chemotherapy Drugs?

LZC. It is classified under 21 CFR 880.6250 as a Class 1 device in the General Hospital panel.

Q: What is the regulatory pathway for Non-Sterile Powder Free Blue Nitrile Examination Gloves Tested for Use with Chemotherapy Drugs?

510(k) clearance (submission type: Traditional).

Q: Who can help prepare an FDA 510(k) submission like Non-Sterile Powder Free Blue Nitrile Examination Gloves Tested for Use with Chemotherapy Drugs?

Innolitics — a medical-device software consultancy — provides regulatory and engineering support for FDA 510(k) submissions. See https://innolitics.com/services/510ks/ or contact https://innolitics.com/contact.

K172864 · Maxter Glove Manufacturing Sdn Bhd · LZC · May 2, 2018 · General Hospital

Device Facts

Record ID	K172864
Device Name	Non-Sterile Powder Free Blue Nitrile Examination Gloves Tested for Use with Chemotherapy Drugs
Applicant	Maxter Glove Manufacturing Sdn Bhd
Product Code	LZC · General Hospital
Decision Date	May 2, 2018
Decision	SESE
Submission Type	Traditional
Regulation	21 CFR 880.6250
Device Class	Class 1

Intended Use

A powder free nitrile examination glove is a disposable device intended for medical purposes that is worn on the examiner's hands and finger to prevent contamination between patient and examiner. In addition, these gloves were tested for use with chemotherapy drugs in accordance with ASTMD6978-05 Standard Practice for Assessment of Medical Gloves to Permeation by Chemotherapy Drugs.

Device Story

Disposable nitrile examination glove; worn on hands/fingers by medical examiners to prevent cross-contamination. Tested for permeation resistance against specific chemotherapy drugs per ASTM D6978-05. Provides barrier protection in clinical settings. Performance verified via bench testing for physical properties, dimensions, and chemical permeation breakthrough times. Not for use with certain drugs (e.g., Carmustine, Thiotepa) due to low permeation times.

Clinical Evidence

Bench testing only. No clinical data required. Testing included dimensions, physical properties, thickness, freedom from holes (ASTM D5151), powder residues (ASTM D6124), chemotherapy drug permeation (ASTM D6978-05), and biocompatibility (ISO 10993: primary skin irritation, dermal sensitization, and in vitro cytotoxicity).

Technological Characteristics

Material: Nitrile. Form: Powder-free, finger-textured, blue. Dimensions: ≥ 230mm length, ≥ 0.05mm thickness. Standards: ASTM D6319-10 (physical properties/dimensions), ASTM D6978-05 (chemo permeation), ISO 10993 (biocompatibility). Non-sterile. Single-use.

Indications for Use

Indicated for use as a disposable medical glove worn by examiners to prevent cross-contamination between patient and examiner. Tested for use with specific chemotherapy drugs.

Regulatory Classification

Identification

A non-powdered patient examination glove is a disposable device intended for medical purposes that is worn on the examiner's hand or finger to prevent contamination between patient and examiner. A non-powdered patient examination glove does not incorporate powder for purposes other than manufacturing. The final finished glove includes only residual powder from manufacturing.

Predicate Devices

Powder Free Nitrile Patient Examination Glove, Blue Colored, Non-Sterile. Tested for Use with Chemotherapy Drugs (K151750)

Related Devices

K220155 — Powder-free Nitrile Examination Gloves Tested for use with Chemotherapy Drugs · Motex Healthcare (Anhui) Co., Ltd. · May 23, 2022
K220353 — Disposal Medical Nitrile Examination Gloves-Tested for Use with Chemotherapy Drugs · Niujian Technology Co., Ltd. · Mar 31, 2022
K130038 — POWDER-FREE NITRILE EXAMINATION GLOVES, BLUE · Hl Rubber Industries Sdn Bhd · Feb 21, 2013
K182554 — Powder Free Nitrile Examination Gloves, Blue, Tested for Use with Chemotherapy Drugs · He Chuang Plastic & Rubber Co., Ltd. · Mar 22, 2019
K202003 — Nitrile Powder Free Examination Glove, Blue Tested for Use with 32 Chemotherapy Drugs and Fentanyl Permeation Resistance Claim · Gmp Medicare Sdn. Bhd. · Feb 24, 2021

Submission Summary (Full Text)

{0}------------------------------------------------ Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue. May 2, 2018 Maxter Glove Manufacturing Sdn Bhd Yap Peak Geeh QA & Regulatory Affairs Manager Lot 6070, Jalan Haji Abdul Manah 6th Miles off Jalan Meru 41050 Klang, Selangor Malaysia Re: K172864 Trade/Device Name: Non-Sterile Powder Free Blue Nitrile Examination Gloves Tested for Use with Chemotherapy Drugs Regulation Number: 21 CFR 880.6250 Regulation Name: Patient Examination Glove Regulatory Class: Class I Product Code: LZA, LZC Dated: March 30. 2018 Received: April 6, 2018 Dear Yap Peak Geeh: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part {1}------------------------------------------------ 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100). Sincerely, Geeta K. Pamidimukkala -S for Tina Kiang, Ph.D. Acting Director Division of Anesthesiology, General Hospital, Respiratory, Infection Control, and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {2}------------------------------------------------ DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration #### Indications for Use Form Approved: OMB No. 0910-0120 Expiration Date: 06/30/2020 See PRA Statement below. #### 510(k) Number (if known) K172864 R1/2001 #### Device Name Non-Sterile Powder Free Blue Nitrile Examination Gloves Tested for Use with Chemotherapy Drugs #### Indications for Use (Describe) A powder free nitrile examination glove is a disposable device intended for medical purposes that is worn on the examiner's hands and finger to prevent contamination between patient and examiner. In addition, these gloves were tested for use with chemotherapy drugs in accordance with ASTMD6978-05 Standard Practice for Assessment of Medical Gloves to Permeation by Chemotherapy Drugs: | Tested Chemotherapy Drug and Concentration | Minimum Breakthrough Detection Time (Minutes) | |-------------------------------------------------|-----------------------------------------------| | Carmustine (BCNU). 3.3mg/ml (3,300ppm) | 8.3 | | Cisplatin. 1.0 mg/ml (1,000ppm) | >240 | | Cyclophosphamide (Cytoxan). 20mg/ml (20,000ppm) | >240 | | Cytarabine 100mg/ml (100,000ppm) | >240 | | Dacarbazine (DTIC), 10.0mg/ml (10,000ppm) | >240 | | Doxorubicin Hydrochloride. 2.0mg/ml (2,000ppm) | >240 | | Etoposide (Toposar), 20.0mg/ml (20,000ppm) | >240 | | Fluorouracil 50.0mg/ml (50,000ppm) | >240 | | Ifosfamide. 50.0mg/ml (50,000ppm) | >240 | | Methotrexate 25mg/ml (25,000ppm) | >240 | | Mitomycin C. 0.5mg/ml (500ppm) | >240 | | Mitoxantrone 2.0mg/ml (2,000ppm) | >240 | | Paclitaxel (Taxol). 6.0mg/ml (6,000ppm) | >240 | | Thiotepa. 10.0mg/ml (10,000ppm) | 38.0 | | Vincristine Sulfate 1.0mg/ml (1,000ppm) | >240 | {3}------------------------------------------------ # 510(K) SUMMARY ## Date Prepared: 30th April 2018 ### 1.0 Submitter: | Name | : | Maxter Glove Manufacturing Sdn Bhd | |-----------|---|---------------------------------------------------------------------------------------------------| | Address | : | Lot 6070 Jalan Haji Abdul Manan, 6th Miles off Jalan Meru, 41050 Klang, Selangor, Malaysia. | | Phone No. | : | 603-33929888 | | Fax No. | : | 603-33923328 | ## 2.0 Name of the device: Non-Sterile Powder Free Blue Nitrile Examination Gloves Tested for Use with Chemotherapy Drugs Common Name Patient Examination Gloves : Brand Name Maxter Classification Name: Polymer Patient Examination Glove (21 CFR 880.6250 Product Code LZA) # 3.0 Identification Of The Legally Marketed Devices that equivalency is claimed: | | Predicate | |-------------------|------------------------------------------------------------------------------------------------------------------------| | Manufacturer | Kossan International Sdn Bhd | | Device Name | Powder Free Nitrile Patient Examination Glove, Blue Colored, Non-Sterile. Tested for Use with Chemotherapy Drugs | | 510(k) Number | K151750 | | Regulation Number | 21 CFR 880.6250 | | Regulatory Name | Patient Examination Glove | | Regulatory Class | I | Patient Examination Gloves Specialty (21 CFR 880.6250 Product Code LZC) ### 4.0 Description of the Device: These patient examination gloves are formulated using nitrile, non-sterile, powder free, meet all the requirements of ASTM D6319 and tested for use with chemotherapy drugs. ### 5.0 Indications for Use statement for the subject device: {4}------------------------------------------------ A Non-Sterile Powder Free Blue Nitrile Examination Glove Tested for Use with Chemotherapy Drugs is a disposable device intended for medical purposes that is worn on the examiner's hands and finger to prevent contamination between patient and examiner. In addition, these gloves were tested for use with chemotherapy drugs in accordance with ASTMD6978-05. | Tested Chemotherapy Drug and Concentration | Minimum Breakthrough Detection Time (Minutes) | |-------------------------------------------------|-----------------------------------------------| | Carmustine (BCNU). 3.3mg/ml (3,300ppm) | 8.3 | | Cisplatin. 1.0 mg/ml (1,000ppm) | >240 | | Cyclophosphamide (Cytoxan). 20mg/ml (20,000ppm) | >240 | | Cytarabine 100mg/ml (100,000ppm) | >240 | | Dacarbazine (DTIC), 10.0mg/ml (10,000ppm) | >240 | | Doxorubicin Hydrochloride. 2.0mg/ml (2,000ppm) | >240 | | Etoposide (Toposar), 20.0mg/ml (20,000ppm) | >240 | | Fluorouracil 50.0 mg/ml (50,000ppm) | >240 | | Ifosfamide 50.0 mg/ml (50,000ppm) | >240 | | Methotrexate 25mg/ml (25,000ppm) | >240 | | Mitomycin C. 0.5mg/ml (500ppm) | >240 | | Mitoxantrone 2.0mg/ml (2,000ppm) | >240 | | Paclitaxel (Taxol) 6.0mg/ml (6,000ppm) | >240 | | Thiotepa 10.0mg/ml (10,000ppm) | 38 | | Vincristine Sulfate 1.0mg/ml (1,000ppm) | >240 | Please note that the following drugs have low permeation time of less than 240minutes: Carmustine (BCNU), 3.3mg/ml: 8.3 Minutes Thiotepa. 10.0mg/ml: 38.0 Minutes # 6.0 Summary of the Technological Characteristics Comparison: Below is the summary of the technological characteristics of the Non-Sterile Powder Free Blue Nitrile Examination Gloves Tested for Use with Chemotherapy Drugs compare to ASTM D6319 or equivalent standards. Chemotherapy claim is similar to predicate device, which has a glove thickness of minimum 0.05mm and is shorter than 270mm but in compliance with the ASTM standards. | Characteristics | Standards | Device Performance | | |----------------------------------------------------------|-----------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | Predicate | Current | | Manufacturer | | Kossan International Sdn Bhd | Maxter Gloves Manufacturing Sdn Bhd | | 510 (K) Number | | K151750 | K172864 | | Dimensions | ASTM D6319-10 | $\geq$ 230mm | $\geq$ 230mm | | Physical Properties | ASTM D6319-10 | Meet | Meet | | Thickness- Finger -palm | ASTM D6319-10 | ≥ 0.05mm | ≥ 0.05mm | | Freedom From Holes | ASTM D6319-10 and ASTM D5151 | Pass | Pass | | Powder Free Residue | ASTM D6319-10 and ASTM D6124 | Meet | Meet | | Resistance to Permeation by Chemotherapy Drugs: | ASTM D6978-05 | | | | Test Chemotherapy Drug | Concentration | Minimum Breakthrough Detection Time (min) | | | Carmustine (BCNU) | 3.3mg/ml | 10.1 | 8.3 | | Cisplatin | 1.0mg/ml | >240 | >240 | | Cyclophosphamide (Cytoxan) | 20mg/ml | >240 | >240 | | Cytarabine | 100mg/ml | >240 | >240 | | Dacarbazine (DTIC) | 10.0mg/ml | >240 | >240 | | Doxorubicin Hydrochloride | 2.0mg/ml | >240 | >240 | | Etoposide (Toposar) | 20.0mg/ml | >240 | >240 | | Ifosfamide | 50.0 mg/ml | >240 | >240 | | Methotrexate | 25mg/ml | >240 | >240 | | Mitomycin C. | 0.5mg/ml | >240 | >240 | | Mitoxantrone | 2.0mg/ml | >240 | >240 | | Paclitaxel (Taxol) | 6.0mg/ml | >240 | >240 | | Thiotepa | 10.0mg/ml | 30.2 | 38.0 | | Vincristine Sulfate | 1.0mg/ml | >240 | >240 | | Warning Statement | | Warning: Please note that the following drugs have extremely low permeation times: Carmustine(BCNU): 10.1 minutes and Thiotepa: 30.2 minutes | Warning : Please note that the following drugs have low permeation time of less than 240 minutes: Carmustine (BCNU): 8.3 minutes and Thiotepa: 38.0 minutes. Do not use with Carmustine or Thiotepa. | | Biocompatibility | Primary Skin Irritation-ISO 10993 | Under the conditions of the study, this is a non-irritant. | Under the conditions of the study, this is a non-irritant. | | | Dermal Sensitization-ISO 10993 | Under the conditions of the study, this is a non-sensitizer. | Under the conditions of the study, this is a non-sensitizer. | | | In vitro Cytotoxicity- ISO 10993 | Not available. | Under the conditions of the study, the device extract was not cytotoxic. | | Intended Use | - | A patient examination glove is a disposable device intended for medical purposes that is worn on the examiner's hand to prevent contamination between patient and examiner. These gloves were tested for use with chemotherapy drugs per ASTM D6978-05 (Reapproved 2013) Standard Practice for Assessment of Medical Gloves to Permeation by Chemotherapy Drugs. | Non-Sterile Powder Free Blue Nitrile Examination Gloves Tested for Use with Chemotherapy Drugs is a disposable device intended for medical purposes that is worn on the examiner's hands and finger to prevent contamination between patient and examiner. In addition, these gloves were tested for use with chemotherapy drugs in accordance with ASTMD6978-05. | | Material | ASTM D6319-10 | Nitrile | Nitrile | | Color | - | Blue, and white | Blue | | Texture | - | Finger Textured | Finger Textured | | Size | Medical Glove Guidance Manual- Labeling | Extra Small | Extra Small | | | | Small | Small | | | | Medium | Medium | | | | Large | Large | | | | Extra Large | Extra Large | | Single Use | Medical Glove Guidance Manual- Labeling | Single use | Single use | Table 1 {5}------------------------------------------------ {6}------------------------------------------------ # 7.0 Summary of Non-Clinical Performance Data The non-clinical performance test results for the subject device met the acceptance criteria in the standard or test method for dimension, physical properties, thickness, {7}------------------------------------------------ freedom from holes, powder residues, chemotherapy permeation, and biocompatibility testing. # 8.0 Summary of Clinical Performance Data Not applicable- clinical data is not needed for the intended use of this subject device. # 9.0 Conclusion Based on intended use, technological characteristics and non-clinical performance data, the Non-Sterile Powder Free Blue Nitrile Examination Gloves Tested for Use with Chemotherapy Drugs is substantially equivalent to the predicate device K151750.